comprehensive -WSS

comprehensive

author：entertainment 2025-09-30 01:02:55 - browse：1

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： BMI, flaws aside, is found to be useful estimate of body fat in youth

WSS

Change Healthcare can notify patients about the breach, HHS says

Bring on the sabbaticals for nurses

The Pandemic Treaty must support building strong health systems

Readout Newsletter: Illumina, CRISPR, Regeneron

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Kaiser's Risant Health gobbled up Geisinger. Who is next?

hotspot

comprehensive

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

Pregnancy ages women, but effects reverse after delivery

State Dept. review finds Biden bears some blame for Afghanistan failures

BMI, flaws aside, is found to be useful estimate of body fat in youth

Cancer drug shortages should be causing more outrage

With trial win, GSK could get blood cancer drug back on market

New air purifier tech could be key to improving indoor air quality

Cancer, immunology, HIV research ensnared in fetal tissue politics

Medicare details structure of new drug price negotiation program

How to increase colonoscopy rates? Looks like an AI can help

knowledge

Bring on the sabbaticals for nurses

With Wegovy coverage, Medicare patients may face high costs

Readout Newsletter: Illumina, CRISPR, Regeneron

Change Healthcare can notify patients about the breach, HHS says

Pregnancy ages women, but effects reverse after delivery

This gene therapy has record $4.25 million price. It's saved children.

entertainment

entertainment

hotspot

explore